PARP inhibitors as first-line maintenance therapy in ovarian cancer: How can data from ESGO 2022 guide clinical practice?

touchCONGRESS for touchONCOLOGY Listen to three experts explore the latest data from the ESGO European Congress on Gynaecological Oncology 2022 on the use of PARP inhibitors in first-line maintenance therapy for advanced ovarian cancer. The experts  Prof. Jonathan Ledermann, UCL Cancer Institute, London, UK Dr David Tan, National University Cancer Institute, Singapore Dr Anna Tinker, BC Cancer, Vancouver, Canada This touchPODCAST is for HCPs only.  This activity is funded by an independent medical education grant from GlaxoSmithKline. This medical education is provided by touchIME. For further information, visit our website: https://touchoncology.com/education/parp-inhibitors-maintenance-esgo2022/